ATHE · Alterity Therapeutics Inc.
AI read · Neutral
The AI's read
Alterity secured a US composition-of-matter patent for ATH434 and is prepping Phase 3 activities in Multiple System Atrophy toward year-end 2026. The patent covers the crystalline mesylate form used in Phase 2 and extends commercial protection. The market reacted, shares jumped about 9.6% on the news, so some upside is already priced. RSI sits at 15, which means the stock was deeply oversold before the pop. Patent life into 2045 and explicit Phase 3 plans add real optionality across neurodegenerative indications. Given the premarket move and choppy macro, we stay neutral until Phase 3 design and regulatory milestones are clearer.